Moving cancer immunotherapy forward through the<i>Journal for ImmunoTherapy of Cancer (JITC</i>)

Romero, Pedro

doi:10.1136/jitc-2019-000001

Cited by 3 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, patients without NSCLC or NSCLC reported a diffuse large Bcell lymphoma reaction. It is worth noting that at least 3% of patients have grade 3 to 4 ammonia, while about 7% of the 123 patients suffering from serious adverse events, and 5% of study patients discontinuing the drug due to this reason [43].…”

Section: -1bbmentioning

confidence: 99%

Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment

Jia-xing

2020

E3S Web Conf.

View full text Add to dashboard Cite

In recent years, the research achievements of immunotherapy were outstanding, especially in the field of cancer treatment. At present, the major breakthroughs have been made in the research of immunotherapy based on programmed death receptor 1 (programmed death 1, PD-1) or programmed death ligand 1 (programmed death-ligand 1, PD-L1) immune checkpoint blockage. The successful application of anti-PD-1/PD-L1 mono clonal antibody in various clinical trials has showed its remarkable potential in caner immunotherapy. However, the results were not always satisfactory that treatment results often show large individual differences between patients, and it’s usually only a small part of patients would respond the treatment. Thus, combination therapy has become a new research focus in anti-PD-1/PD-L1 blockage-based therapy strategy development. This article will review the combination strategies of anti-PD-1/PD-L1 mAbs treatment and discuss the development and the trend of combination immunotherapy.

show abstract

Section: -1bbmentioning

confidence: 99%

Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment

Jia-xing

2020

E3S Web Conf.

View full text Add to dashboard Cite

show abstract

“…Interleukins can create an environment that promotes cancer growth while also being necessary for a successful tumor-directed immune response. 28 , 29 …”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo study: Ethanolic extract leaves of Azadirachta indica Juss. variant of Indonesia and Philippines suppresses tumor growth of hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling

et al. 2022

View full text Add to dashboard Cite

Background: Azadirachta indica Juss. has been shown to suppress cancer progression through a variety of mechanisms. In order to treat cancer progression, cancer immunotherapy is used to stimulate the immune system where immunosuppression is present in tumor microenvironments. Many cancer cells produce a lot of interleukin-6 (IL-6) and signal transducer activator of transcription 3 (STAT3). STAT3 plays a key role in suppressing the expression of critical immune activation regulators. IL‐6‐mediated STAT3 activation is common in the tumor microenvironment. Inhibiting the IL-6/STAT3 signaling pathway has become a therapeutic option for cancer progression. As vimentin is also expressed in hepatic stellate cells boosting cancer survival. We focused on the precise effect of extract from leaves of Azadirachta indica Juss, on inhibiting the IL-6/STAT3 signaling cascade on hepatocellular carcinoma by in vitro and in vivo study. Methods: In the in vitro study, the effect of Azadirachta indica Juss. variant Indonesia and Philippines against the expression of IL-6 and STAT3 was examined in liver cancer cell line. In the in vivo study, 24 male rats (Rattus norvegicus) strain Wistar were induced by diethylnitrosamine and carbon tetrachloride (CCl4). Based on the therapy given, the groups were divided into negative control, positive control, Indonesia extract, and Philippine extract. Expression of IL-6, STAT3, and vimentin were tested using immunohistochemistry staining. The data were analyzed using analysis of variance, which was then followed by the Tukey test. Results: Statistically significant difference in IL-6 and STAT3 was observed between the treatment groups and positive control group by in vitro study and in vivo study. Generally, there is no significant difference between treatment using Indonesian and Philippine leaves. Conclusion: Both therapy doses of Azadirachta indica variant in Indonesia and Philippines were able to reduce IL-6, STAT3 and vimentin expression of hepatocellular carcinoma cell by in vitro and in vivo experiment.

show abstract

“…Since 2019, JITC has experienced a period of exponential growth, publishing more papers in the past 3 years than in the previous 6 years combined, with 539 articles appearing in the journal in 2021 alone. JITC changed publishers in 2019, 6 beginning a new partnership with the British Medical Journal that allowed for enhanced logistical and publishing experiences for authors, reviewers, and readers alike as well as innovative new opportunities to communicate results such as graphical and video abstracts. At the time of the publisher transition, the journal also added two new sections for original research in order to support research into the areas of Immune Cell Therapies and Immune Cell Engineering as well as Oncolytic and Local Immunotherapy.…”

mentioning

confidence: 99%

Celebrating a decade of theJournal for ImmunoTherapy of Cancer

Romero

Gulley

Hwu

et al. 2022

J Immunother Cancer

View full text Add to dashboard Cite

Moving cancer immunotherapy forward through theJournal for ImmunoTherapy of Cancer (JITC)

Cited by 3 publications

References 1 publication

Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment

Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment

In vitro and in vivo study: Ethanolic extract leaves of Azadirachta indica Juss. variant of Indonesia and Philippines suppresses tumor growth of hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling

Celebrating a decade of theJournal for ImmunoTherapy of Cancer

Contact Info

Product

Resources

About